'Huge' results raise hope for cancer breakthrough

In a potential breakthrough in cancer research, scientists at the University of Pennsylvania have genetically engineered patients' T cells — a type of white blood cell — to attack cancer cells in advanced cases of a common type of leukemia.

Two of the three patients who received doses of the designer T cells in a clinical trial have remained cancer-free for more than a year, the researchers said.

Experts not connected with the trial said the feat was important because it suggested that T cells could be tweaked to kill a range of cancers, including ones of the blood, breast and colon.
"This is a huge accomplishment — huge," said Dr. Lee M. Nadler, dean for clinical and translational research at Harvard Medical School, who discovered the molecule on cancer cells that the Pennsylvania team's engineered T cells target.

Findings of the trial were reported Wednesday in two journals.
To build the cancer-attacking cells, the researchers modified a virus to carry instructions for making a molecule that binds with leukemia cells and directs T cells to kill them. Then they drew blood from three patients who suffered from chronic lymphocytic leukemia and infected their T cells with the virus.
When they infused the blood back into the patients, the engineered T cells successfully eradicated cancer cells, multiplied to more than 1,000 times in number and survived for months. They even produced dormant "memory" T cells that might spring back to life if the cancer was to return.

MORE>>>>>>>

No comments: